SAN DIEGO, Oct. 12, 2011 /PRNewswire/ -- Amylin
Pharmaceuticals, Inc. (Nasdaq: AMLN) will webcast its Quarterly
Update Conference Call for the third quarter of 2011 on
Wednesday, October 19, 2011 at
5:00 p.m. ET/2:00 p.m. PT. Daniel M.
Bradbury, Amylin's president and chief executive officer,
will lead the call. On the same date post-market, Amylin will
release financial results for the third quarter of 2011.
The call will be webcast live through the "Investors" section of
Amylin's corporate website and a recording will be made available
following the close of the call. To access the webcast, please log
on to www.amylin.com approximately fifteen minutes prior to the
call to register, download and install any necessary audio
software. For those without access to the Internet, the live call
may be accessed by phone by calling (800) 857-5738
(U.S./Canada) or (415) 228-4970
(international), participant passcode number 7156306. A replay of
the call will also be available by phone beginning approximately
two hours after the close of the call and can be accessed at (866)
415-3327 (U.S./Canada) or (203)
369-0696 (international).
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company dedicated
to improving lives of patients through the discovery, development
and commercialization of innovative medicines. Amylin has developed
and gained approval for two first-in-class medicines for diabetes,
SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide)
injection. Amylin's research and development activities leverage
the Company's expertise in metabolism to develop potential
therapies to treat diabetes and obesity. Amylin is headquartered in
San Diego, California and has a
commercial manufacturing facility in Ohio. Further information on Amylin
Pharmaceuticals is available at www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.